Review Article
Controversies in the Treatment of Early Stage Endometrial Carcinoma
Table 4
Some important studies of chemotherapy in endometrial cancer.
| | | PFS | OS | Toxicity issues |
| | RCT : GOG 122 (advanced stage) | WAR versus chemotherapy (AP) | 38% versus 50% | 42% versus 55% | Treatment-related death 2% versus 4% | | RCT : GOG 177 (Advanced stage) | Chemotherapy : AP versus TAP | 5.3 versus 8.3 | 12.3 versus 15.3 | Grade 3 | | (months) | (months) | neuropathy | | () | () | 1% versus 12% | | Phase II : RTOG 9708 (All stages) | Chemoradiation : pelvic radiation (with concurrent cisplatin) + 4 cycles of TP | All stages: 81%
Stage III = 72% | All stages: 85%
Stage III = 77% | Grade 3 = 16%
Grade 4 = 5% |
|
|
RCT = randomized controlled trial, WAI = whole-abdominal radiation, AP = doxorubicin and cisplatin, TAP = paclitaxel, doxorubicin, cisplatin (+filgrastim), TP = paclitaxel and cisplatin, PFS = progression-free survival, and OS = overall survival.
|
